At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 502 enrolled
Drug / intervention
rapamycin plus 17beta estradiolvalerat-eluting stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized Trial of Rapamycin Plus Estradiol-Eluting Stents Versus Rapamycin-Eluting Stents For The Reduction of Coronary Restenosis (ISAR-PEACE)
In Brief
A Phase 4 clinical trial evaluating rapamycin plus 17beta estradiolvalerat-eluting stent and rapamycin-eluting stent for Coronary Heart Disease. Completed, enrolled 502 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate whether adding estradiol to rapamycin better prevents coronary artery reblockage after drug-eluting stent implantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Heart Disease
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
Study CompletionOct 2006
First PostedNov 2006
TodayJul 2026
First PostedNov 22, 2006
Enrollment StartMar 1, 2005
Study CompletionOct 1, 2006
TodayJul 1, 2026
Posted 19.6 years ago
Interventions
rapamycin plus 17beta estradiolvalerat-eluting stentdevice
rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
rapamycin-eluting stentdevice
rapamycin-eluting stent was implanted due to randomisation